BAAM
NVO

Baker Avenue Asset Management’s Novo Nordisk NVO Stock Holding History

Baker Avenue Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,700
Closed -$218K – 402
2024
Q1 		$218K Buy
+1,700
New +$202K 0.01% 338
2023
Q4 		– Sell
-738
Closed -$67.1K – 1116
2023
Q3 		$67.1K Hold
738
– – ﹤0.01% 485
2023
Q2 		$59.7K Sell
738
-82
-10% -$6.7K ﹤0.01% 499
2023
Q1 		$65.2K Buy
820
+82
+11% +$5.82K ﹤0.01% 497
2022
Q4 		$49.9K Buy
+738
New +$43.3K ﹤0.01% 495

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Baker Avenue Asset Management's NVO Position: Q2 2024 in Review

Baker Avenue Asset Management sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 1,700 shares — an estimated $218K sold.

Baker Avenue Asset Management first reported a position in NVO in Q4 2022 and held it in 5 quarters. The position peaked at $218K in Q1 2024. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Baker Avenue Asset Management reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
  • Baker Avenue Asset Management sold 1,700 Novo Nordisk shares in Q2 2024, an estimated $218K.
  • Baker Avenue Asset Management first reported a position in Novo Nordisk in Q4 2022 and held it in 5 quarters.
  • Baker Avenue Asset Management's Novo Nordisk position peaked at $218K in Q1 2024.
  • 1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Baker Avenue Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.